Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics presented late-breaking data at ENDO 2026 showing lorundrostat significantly reduced heart failure risk biomarkers in patients with uncontrolled hypertension. The post-hoc proteomic analysis of 1,004 participants from the Phase 3 Launch-HTN and Phase 2b Advance-HTN trials showed coordinated reductions in markers of fibrosis and heart failure risk, supporting the drug's potential in HF pathophysiology.
Key figures
- Drug Name
- lorundrostat
- Phase Of Trial
- Phase 3 (Launch-HTN) and Phase 2b (Advance-HTN)
- Pdufa date
- December 22, 2026
- Biomarkers reduced
- 6 of 11 candidate causal risk biomarkers
- Participants analyzed
- 1004
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.